Product
Supplier
Encyclopedia
Inquiry
Home > Analytical Chemistry > Standard > Docetaxel for Sale > 99% Wjite Powder Docetaxel CAS NO (114977-28-5) In Bulk
99% Wjite Powder Docetaxel  CAS NO (114977-28-5) In Bulk buy - large image1
99% Wjite Powder Docetaxel  CAS NO (114977-28-5) In Bulk buy - image1
99% Wjite Powder Docetaxel  CAS NO (114977-28-5) In Bulk buy - image2
99% Wjite Powder Docetaxel  CAS NO (114977-28-5) In Bulk buy - image3
99% Wjite Powder Docetaxel  CAS NO (114977-28-5) In Bulk buy - image4
99% Wjite Powder Docetaxel  CAS NO (114977-28-5) In Bulk buy - image5
99% Wjite Powder Docetaxel  CAS NO (114977-28-5) In Bulk buy - image6

99% Wjite Powder Docetaxel CAS NO (114977-28-5) In Bulk

3 Inquiries

Unit Price: Get Latest Price
CAS No.:

114977-28-5

Grade:

Pharmaceutical Grade

Content:

99%

Port:

Durban

Brand:

Custom

Packaging:

As per customer requirement

Price valid (until):

2024-06-01

Company Type:
Distributor
Location:
South Africa
Qualification:
Main Products:

Sodium Lauryl Ether Sulfate,Caustic Soda,Soda Ash,Citric Acid,Calcium Hypochlorite,Oxalic Acid

  • Product Description

  • Seller Information

  • Inquiry History

  • Description


      Product Detail  


    Docetaxel (CAS No. 114977-28-5): A Chemotherapeutic Marvel

    Enter the realm of docetaxel, a potent chemotherapy agent known by its CAS number 114977-28-5, hailed for its efficacy in combating various cancers. Explore its mechanism of action, clinical applications, and ongoing research endeavors aimed at enhancing its therapeutic potential.

    Docetaxel (114977-28-5): Unraveling the Mechanisms of Anticancer Action

    Delve into the molecular intricacies of docetaxel, CAS number 114977-28-5, as it targets microtubule dynamics to impede cancer cell proliferation. This description elucidates its role in disrupting mitotic spindle function, inducing apoptosis, and restraining tumor growth across a spectrum of malignancies.

    Docetaxel (CAS No. 114977-28-5): Pioneering Precision Oncology

    Discover the pioneering role of docetaxel in the era of precision oncology, where tailored treatment approaches optimize therapeutic outcomes. From its integration into multidisciplinary cancer care regimens to its synergy with targeted therapies, this description explores docetaxel's evolving landscape in personalized medicine.

    Docetaxel (114977-28-5): A Beacon of Hope in Cancer Therapy

    Illuminate the transformative impact of docetaxel on cancer treatment paradigms worldwide. With its CAS number 114977-28-5, this description celebrates docetaxel's role as a beacon of hope, offering survival benefits and improving quality of life for patients battling diverse malignancies.

    Docetaxel (CAS No. 114977-28-5) and Beyond: Innovations in Drug Delivery

    Explore innovations in docetaxel delivery systems aimed at enhancing efficacy and mitigating adverse effects. From nanoparticle formulations to liposomal encapsulation, this description delves into emerging strategies that harness docetaxel's therapeutic potential while minimizing systemic toxicity.

    Docetaxel (114977-28-5): Navigating Adverse Effects and Supportive Care

    Navigate the landscape of docetaxel-associated adverse effects and strategies for supportive care. From hematologic toxicities to neuropathies, this description provides insights into mitigating side effects and optimizing patient tolerance during docetaxel-based cancer therapy.

    Docetaxel (CAS No. 114977-28-5) in Clinical Practice: From Bench to Bedside

    Trace docetaxel's journey from bench to bedside, where translational research and clinical trials have paved the way for its integration into standard cancer care protocols. This description highlights pivotal trials, therapeutic breakthroughs, and ongoing investigations shaping docetaxel's clinical utility.

    Docetaxel (114977-28-5): Bridging Research Frontiers in Oncology

    Peer into the future of docetaxel research, where genomic insights, biomarker discovery, and immunotherapy combinations hold promise for advancing cancer treatment outcomes. This description explores the cutting-edge research endeavors poised to redefine docetaxel's role in the oncology landscape.

    Docetaxel (CAS No. 114977-28-5): Empowering Patients, Inspiring Resilience

    Celebrate the resilience and courage of patients navigating docetaxel-based cancer therapy. With its CAS number 114977-28-5, this description honors their journeys, acknowledges their challenges, and underscores the transformative impact of docetaxel in fostering hope and healing amidst adversity.

    Items Specifications
    1. Classification Docetaxel is a chemotherapy medication belonging to the taxane class of drugs.
    2. Mechanism of Action It works by inhibiting microtubule disassembly, disrupting cell division and ultimately leading to cell death.
    3. Indications - Used in the treatment of various cancers, including breast cancer, lung cancer, prostate cancer, and stomach cancer.
    4. Administration Typically administered intravenously (IV) in a clinical setting under the supervision of a healthcare professional.
    5. Brand Names Marketed under various brand names including Taxotere.
    6. Side Effects Common side effects may include hair loss, nausea, vomiting, diarrhea, and decreased blood cell counts.
    7. Dosage Forms Available as a concentrate solution for infusion.
    8. Development Developed by Sanofi-Aventis (now Sanofi) and was approved for medical use in the United States in 1996.
    9. Clinical Trials Extensively studied in clinical trials across various cancer types and treatment regimens to assess its efficacy and safety.
    10. Combination Therapy Often used in combination with other chemotherapy drugs or alongside radiation therapy to enhance treatment outcomes.
    11. Resistance Some cancer cells may develop resistance to Docetaxel over time, necessitating changes in treatment strategies or the addition of other drugs.
    12. Pharmacokinetics Exhibits nonlinear pharmacokinetics, meaning its plasma concentrations do not increase proportionally with dose.
    13. Precautions Requires careful monitoring during administration due to the potential for severe allergic reactions or hypersensitivity reactions.
    14. Research Areas Ongoing research explores novel formulations and delivery methods to improve efficacy, reduce side effects, and overcome resistance mechanisms.
    15. Patient Education Patients receiving Docetaxel should be educated about potential side effects, the importance of adherence to treatment schedules, and strategies for managing symptoms.


      Product Detail  


    Shop Supply High Qulity Docetaxel Anhydrous CAS 114977-28-5-Detailed Image 1Shop Supply High Qulity Docetaxel Anhydrous CAS 114977-28-5-Detailed Image 2

    Basic Info
    Product Name:

    Docetaxel

    Other Name:

    Benzenepropanoic acid,β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-,(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester,(αR,βS)-;Benzenepropanoic acid,β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-,12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester,[2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]]-;7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.;RP 56976;Docetaxel;Taxotere;N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol;Docetaxol;Docetere;Taxotel;SID 530;Duopafei;Docefrez;BIND 014;Miradocetaxel;CKD 810;CRLX 301;ATI 1123;216252-50-5;129522-72-1

    CAS No.:

    114977-28-5

    Molecular Formula:

    C43H53NO14

    InChIKeys:

    InChIKey=ZDZOTLJHXYCWBA-VCVYQWHSSA-N

    Molecular Weight:

    807.87900

    Exact Mass:

    807.88

    EC Number:

    601-339-2

    HScode:

    2932999099

    Categories:

    Standard

    Characteristics
    PSA:

    224.45000

    XLogP3:

    1.6

    Appearance:

    Off-white Cryst.

    Density:

    1.37 g/cm3

    Melting Point:

    232 °C

    Boiling Point:

    900.5ºC at 760 mmHg

    Flash Point:

    498.4ºC

    Refractive Index:

    1.618

    Water Solubility:

    1.27e-02 g/L

    Storage Conditions:

    Keep tightly closed. Store at +4ºC.

    Vapor Pressure:

    5.61X10-27 mm Hg at 25 deg C (est)

    Hazard Identification

    Classification of the substance or mixture

    Reproductive toxicity, Category 2

    GHS label elements, including precautionary statements

    Pictogram(s)
    Signal word

    Warning

    Hazard statement(s)

    H361 Suspected of damaging fertility or the unborn child

    Precautionary statement(s)
    Prevention

    P203 Obtain, read and follow all safety instructions before use.

    P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...

    Response

    P318 IF exposed or concerned, get medical advice.

    Storage

    P405 Store locked up.

    Disposal

    P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.

    Other hazards which do not result in classification

    no data available

    Handling and Storage

    Precautions for safe handling

    Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

    Conditions for safe storage, including any incompatibilities

    Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.

  • Seller Information
    Business Type:

    Distributor

    Main Products:

    Sodium Lauryl Ether Sulfate,Caustic Soda,Soda Ash,Citric Acid,Calcium Hypochlorite,Oxalic Acid

    Location:

    13 PROTEA PARK MILKWOOD STREET RANGEVIEW GAUTENG 1739

    Payment Terms:

    TT against copy of documents,TT against B/L draft before shipment

    Average lead Time:

    60

    Total Annual Revenue:

    $1 million-$2.5 million

    Total Employees:

    11-50

    Year of Establishment:

    2012

  • Inquiry History
    3 Inquiries
    Country Product Purchase Quantity Date Posted
    United States

    Factory Raw Powder Pharmaceutical Docetaxel CAS 114977-28-5 High Purity 99%

    1 KG Oct 20, 2023
    Nigeria

    Docetaxel

    5 G Apr 13, 2026
    Brazil

    Docetaxel

    1.00 KG Mar 29, 2025
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.